Study presentation
Logotype for Oculis Holding AG

Oculis (OCS) Study presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Oculis Holding AG

Study presentation summary

30 Oct, 2026

Market need and product rationale

  • 2024 dry-eye prescription market in G7 countries was shown at $5bn; calcineurin inhibitors represented 68% of U.S. prescriptions, LFA-1 antagonists 19%, and other treatments 13%.

  • Only 13% of patients experienced lasting relief after 12 months on current treatments; 85%–90% discontinued within 180 days.

  • Licaminlimab is an anti-TNFα antibody fragment formulated as an eye drop; its lower molecular weight is designed to enhance ocular penetration.

  • The candidate targets inflammation and apoptosis; a TNFR1 genetic biomarker is intended to identify patients more likely to respond.

Phase 2 evidence and biomarker

  • Three Phase 2 trials were completed: two symptom-focused studies (85 and 134 patients) and the RELIEF signs study (122 patients); results were described as consistently positive.

  • Phase 2 results showed a more pronounced treatment effect in TNFR1 genotype-positive patients: 5x greater in signs and 7x in symptoms.

  • In RELIEF, Day 43 inferior corneal staining difference versus vehicle was -0.59 in the TNFR1 group (n=12 vs. 11; 90% CI -1.165 to -0.017), compared with -0.12 in the full population; analyses were preliminary.

  • Exploratory analysis found a significant association between TNFR1 and ocular discomfort response at Day 29 (P<0.0001); high responders represented 18% on licaminlimab versus 5% on vehicle (P=0.018).

Safety and tolerability

  • Phase 2a/2b safety data showed at least one TEAE in 18.8% on licaminlimab and 13.8% on vehicle; study-eye ocular TEAEs occurred in 11.5% and 10.2%, respectively.

  • No deaths were reported; treatment-related serious TEAEs were 0% in both groups, and drop comfort was described as consistent with artificial tears.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Oculis